Skip To Main Content
Bedia A. Barkoh on Muck Rack

Bedia A. Barkoh

As seen in: Journal of Clinical Pathology, Archives of Pathology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bedia A.

Contact Bedia A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy

|
By Erin Faber, Horiana B Grosu, Sharjeel Sabir, Bedia A. Barkoh
| Journal of Clinical Pathology Verified
Erin Faber1, Horiana Grosu2, Sharjeel Sabir3, Francis Anthony San Lucas4, Bedia A Barkoh4, Roland L Bassett5, Rajyalakshmi Luthra4, John Stewart1, http://orcid.org/0000-0002-9447-7701Sinchita Roy-Chowdhuri1 1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2 Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Interventional Radiology, The University of Texas MD Anderson Cancer...
Open in Who Shared Issue with article?

Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy

|
By Erin Faber, Horiana B Grosu, Sharjeel Sabir, Bedia A. Barkoh
| Journal of Clinical Pathology Verified
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy Erin Faber1, Horiana Grosu2, Sharjeel Sabir3, Francis Anthony San Lucas4, Bedia A Barkoh4, Roland L Bassett5, Rajyalakshmi Luthra4, John Stewart1, http://orcid.org/0000-0002-9447-7701Sinchita Roy-Chowdhuri1 1Department of Pathology, The University of Texas MD Anderson Cancer Center,...
Open in Who Shared Issue with article?

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era

|
By Mark J Routbort, Santiago Montes-Moreno, Elijah J. Lohman, Bedia A. Barkoh
| PLOS
ASXL1 (additional sex combs like 1) is a gene that is mutated in a number of hematological neoplasms. The most common genetic alteration is c.1934dupG p.Gly646fs. Previous publications have shown that ASXL1 mutations have a negative prognostic impact in patients with MDS and AML, however, controversy exists regarding the molecular testing of ASXL1 c.1934dupG as polymerase splippage over the adjacent homopolymer could lead to a false-positive result.
Open in Who Shared Issue with article?
See all 3 licensed articles (4 Total)